clinical trial · NCT04486378
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
Colorectal Cancer Stage IIColorectal Cancer Stage IIIRO7198457 intravenous (IV)Observational group (no intervention)
brief summary
This is a multi-site, open-label, Phase II, randomized, trial to compare the efficacy of RO7198457 versus watchful waiting in patients with circulating tumor DNA (ctDNA) positive, surgically resected Stage II/III rectal cancer, or Stage II (high risk)/Stage III colon cancer.
started
Mar 8, 2021
primary completion
Nov 1, 2026
completion
Aug 1, 2030
last updated
May 14, 2026
detailed description
Patients will receive up to 15 doses of RO7198457 over the course of trial treatment.
official title
A Multi-site, Open-label, Phase II, Randomized, Controlled Trial to Compare the Efficacy of RO7198457 Versus Watchful Waiting in Resected, Stage II (High Risk) and Stage III Colorectal Cancer Patients Who Are ctDNA Positive Following Resection
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol